DK0801571T3 - Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer - Google Patents

Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer

Info

Publication number
DK0801571T3
DK0801571T3 DK95943134T DK95943134T DK0801571T3 DK 0801571 T3 DK0801571 T3 DK 0801571T3 DK 95943134 T DK95943134 T DK 95943134T DK 95943134 T DK95943134 T DK 95943134T DK 0801571 T3 DK0801571 T3 DK 0801571T3
Authority
DK
Denmark
Prior art keywords
formulations
deoxyadenosion
chloro
soluble
cda
Prior art date
Application number
DK95943134T
Other languages
English (en)
Inventor
Michael Bornstein
Rosemary Rozman
Kevin Francis Long
George Kaon Wong
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Application granted granted Critical
Publication of DK0801571T3 publication Critical patent/DK0801571T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DK95943134T 1994-12-22 1995-12-15 Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer DK0801571T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36208394A 1994-12-22 1994-12-22
PCT/US1995/016418 WO1996019230A1 (en) 1994-12-22 1995-12-15 Soluble 2-chloro-2'-deoxyadenosine formulations

Publications (1)

Publication Number Publication Date
DK0801571T3 true DK0801571T3 (da) 2003-01-06

Family

ID=23424634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95943134T DK0801571T3 (da) 1994-12-22 1995-12-15 Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer

Country Status (15)

Country Link
US (1) US5681822A (da)
EP (1) EP0801571B1 (da)
JP (1) JPH10512549A (da)
AT (1) ATE223221T1 (da)
CA (1) CA2208484C (da)
CZ (1) CZ194297A3 (da)
DE (1) DE69528080T2 (da)
DK (1) DK0801571T3 (da)
ES (1) ES2182920T3 (da)
HU (1) HUT77928A (da)
IL (1) IL116469A0 (da)
PL (1) PL321431A1 (da)
PT (1) PT801571E (da)
WO (1) WO1996019230A1 (da)
ZA (1) ZA9510924B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
MXPA05010635A (es) * 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
FR2873695A1 (fr) * 2004-07-30 2006-02-03 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
US20240077481A1 (en) 2021-03-03 2024-03-07 Ares Trading S.A. Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4908441A (en) * 1988-07-19 1990-03-13 Warner-Lambert Company Deoxyadenosine compounds and methods of making and using the same
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
EP0642347A4 (en) * 1992-05-19 1997-06-18 Scripps Research Inst USE OF 2-HALO-ADENINE DERIVATIVES AS THERAPEUTIC ACTIVE AGENTS AGAINST CHRONIC-MYELOIC LEUKEMIA.

Also Published As

Publication number Publication date
US5681822A (en) 1997-10-28
ES2182920T3 (es) 2003-03-16
EP0801571B1 (en) 2002-09-04
CZ194297A3 (en) 1997-10-15
WO1996019230A1 (en) 1996-06-27
EP0801571A1 (en) 1997-10-22
DE69528080T2 (de) 2003-06-05
ATE223221T1 (de) 2002-09-15
IL116469A0 (en) 1996-03-31
JPH10512549A (ja) 1998-12-02
HUT77928A (hu) 1998-11-30
PT801571E (pt) 2002-12-31
CA2208484C (en) 2008-09-23
DE69528080D1 (de) 2002-10-10
PL321431A1 (en) 1997-12-08
CA2208484A1 (en) 1996-06-27
ZA9510924B (en) 1997-06-23

Similar Documents

Publication Publication Date Title
ZA9510865B (en) Stable 2-chloro-2'-deoxyadenosine formulations
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
TR199700358A2 (xx) �nterferon birle�imler.
ITRM920476A0 (it) Formulazioni galeniche contenenti ciclosporina.
MY131095A (en) Polyethylene protein conjugates.
TR199500778A1 (tr) Suda risperidon formülasyonlari.
ATE257014T1 (de) Lichtbilderzeugungskontrastmitteln
FI972514L (fi) Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
ATE244015T1 (de) Formulierungen fuer faktor ix
PT932397E (pt) Formulacoes em aerossol medicinais compreendendo budesonida
FI921142L (fi) Gelformulationer.
NO993028D0 (no) Vannbaserte alkoholhydroksykarboksylperoksid-sammensetninger, fremstilling og anvendelse herav
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
DK0801571T3 (da) Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
DZ1926A1 (fr) Formulations pharmaceutiques.
JO1907B1 (en) Dissolved compounds of 2-chloro-2-dioxin adenosine
EP0923366A4 (en) SUN PROTECTOR CONTAINING DAMAGED RNS FRAGMENTS
JO1908B1 (en) Static compounds of 2-chloro-2-dioxin adenosine
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli
RU96103721A (ru) Антгельминтное средство
CA2208241A1 (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.
MA22854A1 (fr) Conjugues de proteine et de polyethylene glycol .
IT1288577B1 (it) Struttura di supporto, in particolare composita da attacchi per monosci